Unknown

Dataset Information

0

MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension.


ABSTRACT:

Background

Vascular hyperproliferative disorders are characterized by excessive smooth muscle cell (SMC) proliferation leading to vessel remodeling and occlusion. In pulmonary arterial hypertension (PAH), SMC phenotype switching from a terminally differentiated contractile to synthetic state is gaining traction as our understanding of the disease progression improves. While maintenance of SMC contractile phenotype is reportedly orchestrated by a MEF2C-myocardin (MYOCD) interplay, little is known regarding molecular control at this nexus. Moreover, the burgeoning interest in microRNAs (miRs) provides the basis for exploring their modulation of MEF2C-MYOCD signaling, and in turn, a pro-proliferative, synthetic SMC phenotype. We hypothesized that suppression of SMC contractile phenotype in pulmonary hypertension is mediated by miR-214 via repression of the MEF2C-MYOCD-leiomodin1 (LMOD1) signaling axis.

Methods and results

In SMCs isolated from a PAH patient cohort and commercially obtained hPASMCs exposed to hypoxia, miR-214 expression was monitored by qRT-PCR. miR-214 was upregulated in PAH- vs. control subject hPASMCs as well as in commercially obtained hPASMCs exposed to hypoxia. These increases in miR-214 were paralleled by MEF2C, MYOCD and SMC contractile protein downregulation. Of these, LMOD1 and MEF2C were directly targeted by the miR. Mir-214 overexpression mimicked the PAH profile, downregulating MEF2C and LMOD1. AntagomiR-214 abrogated hypoxia-induced suppression of the contractile phenotype and its attendant proliferation. Anti-miR-214 also restored PAH-PASMCs to a contractile phenotype seen during vascular homeostasis.

Conclusions

Our findings illustrate a key role for miR-214 in modulation of MEF2C-MYOCD-LMOD1 signaling and suggest that an antagonist of miR-214 could mitigate SMC phenotype changes and proliferation in vascular hyperproliferative disorders including PAH.

SUBMITTER: Sahoo S 

PROVIDER: S-EPMC4856285 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension.

Sahoo Sanghamitra S   Meijles Daniel N DN   Al Ghouleh Imad I   Tandon Manuj M   Cifuentes-Pagano Eugenia E   Sembrat John J   Rojas Mauricio M   Goncharova Elena E   Pagano Patrick J PJ  

PloS one 20160504 5


<h4>Background</h4>Vascular hyperproliferative disorders are characterized by excessive smooth muscle cell (SMC) proliferation leading to vessel remodeling and occlusion. In pulmonary arterial hypertension (PAH), SMC phenotype switching from a terminally differentiated contractile to synthetic state is gaining traction as our understanding of the disease progression improves. While maintenance of SMC contractile phenotype is reportedly orchestrated by a MEF2C-myocardin (MYOCD) interplay, little  ...[more]

Similar Datasets

| S-EPMC9588778 | biostudies-literature
| S-EPMC7147427 | biostudies-literature
| S-EPMC6814199 | biostudies-literature
2021-06-01 | E-MTAB-10425 | biostudies-arrayexpress
2023-01-27 | GSE207101 | GEO
| S-EPMC6391010 | biostudies-literature
| S-EPMC8745077 | biostudies-literature
| S-EPMC8262341 | biostudies-literature
| S-EPMC9677683 | biostudies-literature
| S-EPMC6600981 | biostudies-literature